Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.
Domchek, S Robson, M Im, S Senkus, E Xu, B Masuda, N Delaloge, S Li, W Armstrong, Anne C Conte, P
Domchek, S
Robson, M
Im, S
Senkus, E
Xu, B
Masuda, N
Delaloge, S
Li, W
Armstrong, Anne C
Conte, P
Citations
Altmetric:
Abstract
Description
Date
2018-02-14
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. 2018, 78(4 Suppl): P5-21-12 Cancer Res